G

Grifols SA
D

GRFS

8.71000
USD
0.18
(2.05%)
مغلق
حجم التداول
20,988
الربح لكل سهم
0
العائد الربحي
-
P/E
35
حجم السوق
5,919,570,323
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    A
    ARRY
    -0.79000
    (-10.35%)
    6.84500 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Grifols SA

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.